Long-term heartburn-pill use is tied to higher kidney and dementia risk

Some of the most widely used stomach-acid medications in the world have drawn repeated scrutiny for what years of daily use might do beyond the gut. Proton pump inhibitors, the class that includes omeprazole and similar drugs, are highly effective against heartburn and ulcers, but a growing set of studies has linked long-term use to higher rates of kidney disease and dementia. The findings do not prove the pills cause those conditions, yet they have prompted doctors to rethink how long patients should stay on them.

How proton pump inhibitors work

Proton pump inhibitors, often shortened to PPIs, shut down the tiny cellular pumps in the stomach lining that produce acid. That makes them powerful tools for healing ulcers, controlling acid reflux, and preventing bleeding in high-risk patients. Millions of people take them, many bought over the counter, and a substantial share keep taking them for months or years, sometimes long after the original reason has faded. That pattern of prolonged, sometimes unnecessary use is exactly what researchers have flagged as the concern.

The drugs are genuinely useful, which is part of the problem. Because they are cheap, available without a prescription, and highly effective at relieving symptoms, they are easy to keep refilling indefinitely. Guidelines generally call for using the lowest effective dose for the shortest necessary time, but real-world use often drifts far past that advice.

The signal on dementia

The link to cognitive decline has attracted particular attention. A study published in the journal Neurology found that people aged 45 and older who took prescription PPIs for more than about 4.4 years had a 33 percent higher rate of newly diagnosed dementia than those who never used the drugs. The association held after researchers accounted for factors such as age, sex, and conditions like high blood pressure and diabetes.

The authors described their result as Class III evidence, a designation that signals a meaningful but not definitive association. In other words, the study can show that long-term PPI users developed dementia more often, but it cannot by itself prove the medication was the cause. Cumulative reviews of the broader literature echo that caution while noting that the pattern has now appeared in multiple datasets.

The strain on the kidneys

Kidney risk is the other major theme. Multiple analyses have connected long-term PPI use to a higher likelihood of chronic kidney disease and its progression. A systematic review and meta-analysis indexed by the National Library of Medicine pooled results from many observational studies and reported elevated rates of chronic kidney disease among PPI users compared with people who did not take the drugs or who used a different class of acid reducers.

The kidneys are especially worth watching because early damage is often silent. Chronic kidney disease can advance for years without obvious symptoms, so a modest increase in risk spread across a huge population of long-term users can translate into a substantial number of cases. That is why researchers treat even a moderate association as clinically relevant rather than dismissing it.

Why association is not the same as cause

Nearly every study raising these alarms shares a structural limitation: it observes what happens to people already taking the drugs rather than assigning them at random. That design cannot rule out confounding, the possibility that PPI users differ from non-users in ways that independently raise their risk. People on long-term acid suppression may be older, sicker, or taking other medications, any of which could help explain higher rates of kidney disease or dementia.

A broad systematic review of long-term PPI use and the risk of kidney disease, dementia, and fractures made that tension explicit, finding statistically significant associations across several outcomes while stressing that bias and the inability to establish causation limit how far the results can be pushed. Proving cause would require randomized trials that follow patients for years, which are difficult to run for a drug already in mass use.

What patients and doctors are doing with the evidence

The practical response has not been to abandon PPIs but to use them more deliberately. Federally supported research on medication safety, summarized through the National Institutes of Health, has reinforced a broader push to periodically review long-standing prescriptions and stop those no longer needed. For PPIs, that means confirming there is still a clear reason to continue, trying the lowest effective dose, and considering step-down approaches for people whose symptoms are under control.

Patients are generally advised not to stop the drugs abruptly on their own, since acid can rebound and underlying conditions such as ulcers or severe reflux may still require treatment. The safer path runs through a clinician who can weigh the benefit against the accumulating risk signals. For someone taking a PPI for years without a pressing medical reason, that conversation is where the research on kidney and brain risk becomes actionable rather than merely alarming.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview